India Globalization Capital/$IGC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About India Globalization Capital
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.
Ticker
$IGC
Sector
Primary listing
AMEX
Employees
70
Headquarters
Website
IGC Metrics
BasicAdvanced
$38M
-
-$0.08
1.48
-
Price and volume
Market cap
$38M
Beta
1.48
52-week high
$0.50
52-week low
$0.25
Average daily volume
1.1M
Financial strength
Current ratio
1.248
Quick ratio
0.341
Long term debt to equity
2.303
Total debt to equity
3.323
Profitability
EBITDA (TTM)
-6.381
Gross margin (TTM)
45.97%
Net profit margin (TTM)
-477.92%
Operating margin (TTM)
-525.85%
Revenue per employee (TTM)
$20,000
Management effectiveness
Return on assets (TTM)
-47.05%
Return on equity (TTM)
-90.87%
Valuation
Price to revenue (TTM)
25.027
Price to book
5.81
Price to tangible book (TTM)
8.66
Price to free cash flow (TTM)
-6.746
Free cash flow yield (TTM)
-14.82%
Free cash flow per share (TTM)
-0.062
Growth
Revenue change (TTM)
24.95%
Earnings per share change (TTM)
-61.55%
3-year revenue growth (CAGR)
35.62%
10-year revenue growth (CAGR)
-17.21%
3-year earnings per share growth (CAGR)
-36.58%
10-year earnings per share growth (CAGR)
-10.33%
IGC News
AllArticlesVideos
IGC Pharma, Inc. Receives Third Award from the NIA for Excellence in Code Clarity, Reproducibility, and Usability for Alzheimer's Detection
Accesswire2 days ago
IGC Pharma Expands CALMA Phase 2 Trial to Island Health's Royal Jubilee Hospital in Canada
Accesswire1 week ago
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q1 results. We believe more positive clinical data and progress in 2025 to be strong catalysts for stock.
Accesswire2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for India Globalization Capital stock?
India Globalization Capital (IGC) has a market cap of $38M as of September 11, 2025.
What is the P/E ratio for India Globalization Capital stock?
The price to earnings (P/E) ratio for India Globalization Capital (IGC) stock is 0 as of September 11, 2025.
Does India Globalization Capital stock pay dividends?
No, India Globalization Capital (IGC) stock does not pay dividends to its shareholders as of September 11, 2025.
When is the next India Globalization Capital dividend payment date?
India Globalization Capital (IGC) stock does not pay dividends to its shareholders.
What is the beta indicator for India Globalization Capital?
India Globalization Capital (IGC) has a beta rating of 1.48. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.